Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Corcept Therapeutics Provides Miricorilant Clinical Development Update

By: Corcept Therapeutics Incorporated via GlobeNewswire

December 08, 2022 at 08:00 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced an update to its programs evaluating the proprietary selective cortisol modulator miricorilant in patients with antipsychotic-induced weight gain (AIWG) and non-alcoholic steatohepatitis (NASH).

“Miricorilant did not reverse AIWG in either our GRATITUDE or GRATITUDE II trials,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “However, miricorilant was clearly active in the liver. We will present full results at a medical conference next year.”

“Based on multiple, replicated pre-clinical results as well as on the results of our Phase 1 study in which miricorilant significantly reduced weight gain experienced by healthy volunteers administered olanzapine [Journal of Clinical Psychopharmacology (Hunt 2021)], we plan to further study miricorilant’s potential to prevent AIWG,” added Dr. Guyer.

“Miricorilant continues to demonstrate great promise as a treatment for NASH,” added Dr. Guyer. “Our on-going dose-finding study has identified a range of doses, all substantially lower than our originally tested doses, that appear to cause large reductions in liver fat, without causing excessive liver irritation. We plan to start a Phase 2 trial next year.”

About Corcept Therapeutics

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators as potential treatments for patients with Cushing’s syndrome, ovarian, prostate and adrenal cancer, ALS, weight gain caused by the use of antipsychotic medications and liver disease. Corcept’s drug Korlym^® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.

Forward-Looking Statements

Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties include, but are not limited to, our ability to operate our business, conduct our clinical trials and achieve our other goals during the COVID-19 pandemic; risks related to the development of our product candidates, including their clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property. These and other risks are set forth in our SEC filings, which are available at our website and the SEC’s website.

In this press release, forward-looking statements include those concerning the development of miricorilant, including its clinical attributes, regulatory approvals, mandates and oversight, and other requirements; our trials involving miricorilant, including their design, results and probability of success. We disclaim any intention or duty to update forward-looking statements made in this press release.

CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	244.19	+0.00 (0.00%)
AAPL	290.55	+0.00 (0.00%)
AMD	475.50	-0.00 (-0.00%)
BAC	54.42	+0.00 (0.00%)
GOOG	362.29	+0.00 (0.00%)
META	584.59	+0.00 (0.00%)
MSFT	403.41	+0.00 (0.00%)
NVDA	208.19	+0.00 (0.00%)
ORCL	205.81	+0.00 (0.00%)
TSLA	396.68	+0.00 (0.00%)